Literature DB >> 12852232

Mast cell tumors in the dog.

Cheryl A London1, Bernard Seguin.   

Abstract

The most common skin tumor in dogs is the mast cell tumor (MCT), with an incidence of close to 20% in the canine population. MCTs range from relatively benign to extremely aggressive, leading to metastasis and eventual death from systemic disease. Although surgical removal with or without radiation therapy may cure most patients with low-grade MCTs, there are no effective treatments for dogs with aggressive high-grade MCTs. This article reviews the current understanding of MCT biology with regard to diagnosis, staging, identification of prognostic indicators, and appropriate treatment planning.

Entities:  

Mesh:

Year:  2003        PMID: 12852232     DOI: 10.1016/s0195-5616(03)00003-2

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  28 in total

1.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.

Authors:  S Rodriguez; K Fadlalla; T Graham; B Tameru; C D Fermin; T Samuel
Journal:  J Comp Pathol       Date:  2012-01-30       Impact factor: 1.311

3.  Generation and characterization of novel canine malignant mast cell line CL1.

Authors:  Tzu-Yin Lin; Rachael Thomas; Pei-Chien Tsai; Matthew Breen; Cheryl A London
Journal:  Vet Immunol Immunopathol       Date:  2008-10-11       Impact factor: 2.046

4.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

5.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

6.  Subcutaneous malignant mast cell tumor in a Japanese macaque (Macaca fuscata).

Authors:  Kosuke Tsugo; Tomoe Kinoshita; Ko Kadowaki; Go Sugahara; Emiko Saito; Shigehisa Kawakami; Yumi Une
Journal:  Primates       Date:  2016-10-19       Impact factor: 2.163

7.  In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor.

Authors:  Marcia Kazumi Nagamine; Daniel S Sanches; Katia C Pinello; Luciana Neves Torres; Gregory Mennecier; Andréia O Latorre; Heidge Fukumasu; Maria Lucia Zaidan Dagli
Journal:  Vet Res Commun       Date:  2011-04-07       Impact factor: 2.459

8.  In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA).

Authors:  K C Pinello; M Nagamine; T C Silva; P Matsuzaki; H V Caetano; L N Torres; H Fukumasu; J L Avanzo; J M Matera; M L Z Dagli
Journal:  Vet Res Commun       Date:  2009-01-14       Impact factor: 2.459

9.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

10.  IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Authors:  K Bauer; E Hadzijusufovic; S Cerny-Reiterer; G Hoermann; M Reifinger; A Pirker; P Valent; M Willmann
Journal:  Vet Comp Oncol       Date:  2016-08-09       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.